Literature DB >> 1688601

In vivo replication and reversion to wild type of a neutralization-resistant antigenic variant of hepatitis A virus.

S M Lemon1, L N Binn, R Marchwicki, P C Murphy, L H Ping, R W Jansen, L V Asher, J T Stapleton, D G Taylor, J W LeDuc.   

Abstract

Six seronegative owl monkeys were intravenously inoculated with an antigenic variant (S18) of hepatitis A virus that is highly adapted to growth in cell culture and resists neutralization by monoclonal antibodies due to replacement of aspartic acid 70 of capsid protein VP3 with histidine. Each developed hepatitis 22-33 days after inoculation. Virus in feces, serum, and liver was quantified by radioimmunofocus assay. Viremia developed 7-11 days after inoculation, in parallel with fecal shedding of virus, and persisted for a mean of 20.5 days. Although the antigenic variant was recovered from feces or liver of three animals, virus in liver at the time of enzyme elevations was predominantly wild-type antigenic phenotype. Virus was not recovered from liver 96 days after challenge. These studies further define virologic events in hepatitis A and show that in vivo replication of an antigenic variant was restricted compared with that of wild-type virus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688601     DOI: 10.1093/infdis/161.1.7

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  A single mutation in the glycophorin A binding site of hepatitis A virus enhances virus clearance from the blood and results in a lower fitness variant.

Authors:  M Isabel Costafreda; Enric Ribes; Angels Franch; Albert Bosch; Rosa M Pintó
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Antigenic and genetic variation in cytopathic hepatitis A virus variants arising during persistent infection: evidence for genetic recombination.

Authors:  S M Lemon; P C Murphy; P A Shields; L H Ping; S M Feinstone; T Cromeans; R W Jansen
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

Review 3.  Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Christopher M Walker
Journal:  Cold Spring Harb Perspect Med       Date:  2019-09-03       Impact factor: 6.915

4.  Comparison and characterization of immunoglobulin G subclasses among primate species.

Authors:  M H Shearer; R D Dark; J Chodosh; R C Kennedy
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 5.  Hepatitis A Virus Genome Organization and Replication Strategy.

Authors:  Kevin L McKnight; Stanley M Lemon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-12-03       Impact factor: 6.915

6.  PCR-SSCP analysis of 5'-nontranslated region of hepatitis A viral RNA: comparison with clinicopathological features of hepatitis A.

Authors:  K Fujiwara; O Yokosuka; T Ehata; F Imazeki; H Saisho
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

7.  Animal-derived antigenic variants of foot-and-mouth disease virus type A12 have low affinity for cells in culture.

Authors:  E Rieder; B Baxt; P W Mason
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Mimicry of the immunodominant conformation-dependent antigenic site of hepatitis A virus by motifs selected from synthetic peptide libraries.

Authors:  S Mattioli; L Imberti; R Stellini; D Primi
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

9.  Association between severity of type A hepatitis and nucleotide variations in the 5' non-translated region of hepatitis A virus RNA: strains from fulminant hepatitis have fewer nucleotide substitutions.

Authors:  K Fujiwara; O Yokosuka; T Ehata; H Saisho; N Saotome; K Suzuki; K Okita; K Kiyosawa; M Omata
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

10.  Utilization of chimeras between human (HM-175) and simian (AGM-27) strains of hepatitis A virus to study the molecular basis of virulence.

Authors:  G Raychaudhuri; S Govindarajan; M Shapiro; R H Purcell; S U Emerson
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.